Session 7: The Power of Harnessing RWD from Wearables
Gabriela Lavezzari, PhD, MBA
Senior Director, US R&D Policy and Scientific Affairs
GlaxoSmithKline, United States
In today’s healthcare system, we have greater access to technology with infinite amount of data literally at our fingertips. Wearable technology has introduced a new way to collect additional patient information by providing access to the real-world patient experience. This session will investigate case studies of current efforts aimed at using wearable technologies for drug development and regulatory decision-making along with lesson learned from the medical device community on medical devices that won new indications based on RWE.
Learning Objective : At the conclusion of this session, participants should be able to:
- Identify areas where medical devices have successfully used RWE for regulatory decision-making
- Discuss case studies that showcase advances in the use of wearable technologies
- Identify areas where immediate regulatory policies are needed to streamline the use of wearable technologies for regulatory decision-making in drug development
The Power of Harnessing RWD from Wearables: Pierre-Alexandre Fournier, MSc
Co-Founder and CEO
The Power of Harnessing RWD from Wearables: George Savage, MD
Co-founder and Chief Medical Officer
Proteus Digital Health, United States
Have an account?